Can Remicade (infliximab) cause a runny nose and cough?

Can Remicade Cause Runny Nose and Cough?

Yes, Remicade (infliximab) can cause both runny nose and cough, primarily as manifestations of upper respiratory tract infections, which are among the most common adverse reactions to this medication.

Understanding the Mechanism

Remicade is an anti-TNF-alpha biologic that suppresses immune function, making patients approximately twice as susceptible to infections compared to baseline 1. The medication's immunosuppressive effects create vulnerability to respiratory infections that manifest with these symptoms.

Clinical Evidence for Respiratory Symptoms

Upper Respiratory Tract Infections

Upper respiratory tract infections are explicitly listed as one of the most common side effects of infliximab therapy 2. In clinical trials:

• Upper respiratory tract infection was reported in 32% of REMICADE-treated patients versus 25% in placebo groups 3
• These infections commonly present with cough, pharyngitis, sinusitis, and rhinitis 2
• Most upper respiratory infections are not serious but require monitoring 1

Specific Respiratory Manifestations

The FDA drug label for Remicade documents the following respiratory symptoms 3:

• Coughing: 12% of patients
• Pharyngitis: 12% of patients
• Sinusitis: 14% of patients
• Bronchitis: 10% of patients

Critical Distinction: Infection vs. Infusion Reaction

Infusion-Related Reactions

Cough can also occur as part of an acute infusion reaction during or within 24 hours of Remicade administration 4, 2. High-grade infusion reactions may include:

• Cough
• Shortness of breath
• Wheezing
• Chest tightness
• Hypoxemia

These reactions occur in 3-22% of patients and require immediate medical attention 2.

Infectious Complications

When cough and runny nose develop days to weeks after infusion, infection is the more likely etiology 1. The guideline evidence emphasizes that infections are the most common adverse events with infliximab, with upper respiratory tract infections being the predominant type 1.

Clinical Management Algorithm

When a patient on Remicade develops runny nose and cough:

1. Assess timing relative to infusion:

   • Within 24 hours → Consider infusion reaction
   • Days to weeks later → Suspect infection

2. Evaluate for serious infection indicators:

   • Fever
   • Productive cough
   • Dyspnea
   • Systemic symptoms (fatigue, malaise)

3. Rule out opportunistic infections 1:

   • Tuberculosis (especially if cough persists >2 weeks)
   • Pneumocystis pneumonia
   • Fungal infections (histoplasmosis, coccidioidomycosis)
   • Bacterial pneumonia

4. Management approach:

   • Simple upper respiratory symptoms without fever: Supportive care with close monitoring
   • Fever or systemic symptoms: Discontinue infliximab and initiate workup 1
   • Serious infection confirmed: Anti-TNF therapy should be discontinued 1

Patient Education Requirements

The FDA-approved medication guide explicitly instructs patients to report these symptoms 3:

• "Report to your physician signs of infection, such as cough, aches, fever, and chills"
• Patients should contact their physician immediately if respiratory symptoms develop

Important Caveats

Pediatric Considerations

In pediatric patients with Crohn's disease, infections were reported in 56% of patients, with upper respiratory tract infection and pharyngitis being most common 3. The frequency is notably higher than in adults.

Risk Stratification

Patients at highest risk for infectious complications include those with 1:

• Diabetes
• Chronic lung disease (COPD)
• Concurrent immunosuppressive therapy
• History of recurrent infections

Serious Respiratory Infections

While most upper respiratory infections are mild, serious lower respiratory tract infections including pneumonia can occur 2, 3, 5. Japanese surveillance data identified 108 cases of bacterial pneumonia, 22 cases of Pneumocystis pneumonia, and 14 cases of tuberculosis among 5000 infliximab-treated patients 5.

Bottom Line for Clinical Practice

Runny nose and cough in Remicade patients should trigger evaluation for infection rather than being dismissed as benign side effects. While most cases represent common upper respiratory infections that resolve with supportive care, the immunosuppressive nature of infliximab necessitates vigilance for progression to serious infections. Any patient with fever, persistent symptoms beyond one week, or systemic manifestations requires prompt evaluation and potential discontinuation of therapy pending infectious workup.